Trial Profile
Ultra-Short Acting Insulin Versus Short Acting Insulin Effect on Postprandial Hyperglycemia AKA RCT Comparing Viaject Versus Humalog in Pumps: Effect on Postprandial Glycemia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 09 Feb 2017 Status changed from suspended to withdrawn prior to enrolment.
- 01 Feb 2011 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
- 19 Feb 2010 New trial record